Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study

By sjmartinez • February 24, 2023

Sofen H, Bissonnette R, Yosipovitch G, Silverberg JI, Tyring S, Loo WJ, Zook M, Lee M, Zou L, Jiang GL, Paolini JF. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study. EClinicalMedicine. 2023 Feb 3;57:101826. doi: 10.1016/j.eclinm.2023.101826. PMID: 36816342; PMCID: PMC9932343.

Tags: Dermatology, Olive View DoM, Publications

Unraveling the autoimmune architecture of pemphigus: from B-cell depletion to network-based immune engineering

Shafiei-Jahani P, Li X, Akbari A, Vera A, Haniff E, Carlisle R, Akbari O, Holland V. Unraveling the autoimmune architecture of pemphigus: from B-cell depletion[...]

Cerebriform Ridges on the Scalp Signaling a Tumor in the Brain

Park A, Kenney S, Kellogg C, Castillo JR, Bergheim T. Cerebriform Ridges on the Scalp Signaling a Tumor in the Brain. Perm J. 2026 Jul[...]

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial

Mease PJ, Chandran V, Armstrong AW, Blanco R, Ogdie A, Siegel EL, Gottlieb AB, Zeng X, Thaçi D, Kishimoto M, Schulze-Koops H, Kivitz A, Dokoupilová[...]